DURHAM, N.C., July 26, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the publication of preclinical results with Synthetic Enzyme-Armed Killer (SEAKER) cells in solid tumor melanomas in the peer-reviewed journal Cancer Immunology Research.
DURHAM, N.C., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a nclinical stage immuno-oncology company working to redefine cancer ntreatment using best-in-class cellular immunotherapies, announced a nresearch collaboration with Yeda Research and Development Company Ltd. n(Yeda), the commercial arm of the Weizmann Institute of Science, to nevaluate the applications of the Synthetic Immune Niche (SIN) ntechnology, developed by Weizmann Institute’s researchers to enhance thenexpansion and function of human cytokine induced killer (CIK) cells nexpressing chimeric antigen receptors (CARs).
Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today positive results from a prospective, observational, first-in-human study to evaluate the safety and effectiveness of the Merit WRAPSODY Endoprosthesis. The WRAPSODY Endoprosthesis is a self-expanding, cell-impermeable endoprosthesis designed for the treatment of arteriovenous (“AV”) fistula access circuit stenosis and AV graft access circuit stenosis.
CoImmune Appoints Michael Fekete and Greg Tibbitts to its Board of Directors